• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Johnson & Johnson Is Pulling Back to Retest its Breakout Zone

The broad market may be soft for another week but if I find more stocks in a similar position as JNJ I won't see a reason to join the bear camp.
By BRUCE KAMICH
May 14, 2020 | 02:52 PM EDT
Stocks quotes in this article: JNJ

Wednesday evening during the Mad Money program Jim Cramer mentioned Johnson & Johnson (JNJ) as a company that was less risky than some of the vaccine makers that have gotten frothy lately. Let's check out their charts.  

 
In this daily bar chart of JNJ, below, we can see that prices made a slight new high this year after plunging sharply in February and March. Prices have drifted lower from late April into May but remain above the rising 50-day moving average line and the rising 200-day moving average line. The trading volume was very heavy into the March low and has tapered off over the past few weeks.
 
The On-Balance-Volume (OBV) line has declined sharply from early February to late March and then bounced into April before weakening again. The Moving Average Convergence Divergence (MACD) oscillator turned bullish in early April and by the end of the month it had turned lower for a take profit sell signal.   
 
 
In this weekly Japanese candlestick chart of JNN, below, we can see a long sideways consolidation pattern capped on the upside around the $150 area. Prices broke above this ceiling briefly in February but last month we moved to yet a new high for the move up.
 
The recent candle patterns show a couple of lower shadows suggesting that traders and investors are rejecting the recent lows. The OBV line is bullish on this time frame and so is the MACD oscillator. 
 
 
 
In this first Point and Figure chart of JNJ, below, we can see that prices have retreated a bit after the breakout at $153.96. An upside price target in the $183 area is being projected. 
 
 
In this second Point and Figure chart of JNJ, below, we used a 5-box reversal to filter out jiggles of 3-boxes. Here we can see a target of $220. The pullback here looks "normal" and not the start of a new down move.  
 
 
 
Bottom line strategy: With a number of market observers now fearing the next leg of the bear market, it is interesting to me to see JNJ making a pullback to its major breakout area. The broad market may be soft for another week but if I find more stocks in a similar position as JNJ I will not see a reason to join the bear camp.
 

(Johnson & Johnson is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells JNJ? Learn more now.)

 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Health Care Equipment & Services | Healthcare | Personal Products | Pharmaceuticals | Mad Money

More from Investing

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login